A federal jury in Chicago said on Thursday that Endo International’s Auxilium unit was not responsible for the heart attack a man suffered while using the company’s testosterone replacement drug Testim. The verdict was a victory for the drugmaker in its first trial over allegations it defectively designed Testim, a skin gel, and negligently misrepresented its risks. Thursday’s verdict involved Steve Holtsclaw of Tennessee, who had been using Testim for more than half a year to treat chronic fatigue. He suffered a heart attack in July 2014 and was hospitalized twice, but has since recovered.
This site uses cookies to help personalise content, tailor your experience and to keep you logged in if you register.
By continuing to use this site, you are consenting to our use of cookies.
